Abnormal Methylation of
Tumor Suppressor Ggenes Occurs in Sporadic Breast Cancer
(Russian Academy of Medical
Science-November 5, 2003)
"Multiplex methylation-sensitive
PCR was employed in studying the
methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF,
CDH1, MGMT, HIC1, and N33 promoter regions in breast cancer (105 tumors),"
researchers in Russia report.
"Methylation was often
observed for the two major suppressor genes involved in controlling the cell
cycle through the Cdk-Rb-E2F signaling pathway, RB1 (18/105, 17%) and p16
(59/105, 56%); both genes were methylated in 13 tumors," wrote V.V.
Zemlyakova and colleagues, Russian Academy of Medical Science, Medical
Genetics Research Center.
The researchers concluded: "Methylation
involved p15 in two (2%) tumors; CDH1, in 83 (79%) tumors; MGMT, in eight
(8%) tumors, and
N33, in nine (9%) tumors. The p14 promoter was not methylated in the tumors
examined."
Zemlyakova and colleagues
published their study in Molecular Biology (Abnormal methylation of
several tumor suppressor genes in sporadic breast cancer. Mol Biol-engl Tr,
2003;37(4):591-597).
For additional information,
contact V.V. Zemlyakova, Russian Academy of Medical Science, Medical
Genetics Research Center, Moscow 115478, Russia.
The information in this
article comes under the major subject area of Oncology. This article was
prepared by Biotech Week editors from staff and other reports.
©Copyright 2003, Biotech
Week via
NewsRx.com &
NewsRx.net
This story has been adapted from a news
release issued by
NewsRx.com &
NewsRx.net